ChemDiv and UTMB Partner To Widen its Screening Research Capabilities | India Pharma Outlook

ChemDiv and UTMB Partner To Widen its Screening Research Capabilities

India Pharma Outlook Team | Tuesday, 02 January 2024

 India Pharma Outlook Team

ChemDiv, a global leader in drug discovery solutions, announced a strategic partnership with the University of Texas Medical Branch (UTMB) to expand its inventory and promote the institution's High-throughput Screening (HTS) research programs.

The firm's comprehensive suite of fully integrated research & development services offers UTMB unparalleled support in its pursuit of groundbreaking medical research. By leveraging ChemDiv's 32 years of experience, advanced capabilities, and a seasoned team of experts, UTMB aims to push the boundaries of medical research and translate discoveries into tangible treatments for pressing medical needs, as per pharmabiz

“At ChemDiv, we are dedicated to catalyzing pioneering research, and our collaboration with UTMB exemplifies our commitment to advancing healthcare globally,” said Bill Farley, CEO of ChemDiv. “Our team’s expertise and cutting-edge resources are poised to significantly augment UTMB’s HTS research center, accelerating the discovery of novel therapeutic solutions.”

ChemDiv is committed to collaborating in the discovery and development of novel medicines based on its proprietary chem-bio platforms: molecular glues, stabilizers, and degraders; covalent and non-covalent binders; and bifunctional compounds for synergistic action and synthetic lethality.

Chemical Diversity (ChemDiv) is a San Diego, California-based contract research business. It provides research and development services to pharmaceutical and biotech industries. ChemDiv has assisted clients in developing therapies and medications for disorders affecting the central nervous system, oncology, inflammatory, metabolic, infectious, and other systems. 

Identification of a biological target (protein production, assay development) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models) to proof of concept and pivotal clinical trials of drug candidates (Phase I, II, III, IV) and market access assistance are among the services provided.

© 2024 India Pharma Outlook. All Rights Reserved.